



1614
D#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 13 2001
TECH CENTER 1600/2900

Applicants: Jordan J.N. Tang and Arun K. Ghosh

Serial No.: 09/603,713

Art Unit: 1614

Filed: June 27, 2000

Examiner: Not Yet Assigned

For: *INHIBITORS OF MEMAPSIN 2 AND USE THEREOF*

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the documents cited therein.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No.

01-2507.

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 99/64587 A1	12-16-1999	Rhon-Poulenc Rorer	PCT
WO 00/17369 A3	03-30-2000	Pharmacia & Upjohn Co.	PCT
WO 00/23576 A3	04-27-2000	Vivian Hook	PCT
WO 00/47618 A2	08-17-2000	Elan Pharmaceuticals, Inc.	PCT
WO 00/58479 A1	10-05-2000	Amgen, Inc.	PCT
WO 00/77030 A1	12-21-2000	Elan Pharmaceuticals, Inc	PCT

Publications

ERMOLIEFF, et al., "Proteolytic activation of recombinant Pro-memapsin 2 (Pro- β -secretase) studied with new flourogenic substrates," *Biochemistry* 39(40):12450-12456 (2000).

GHOSH, et al., "Design of potent inhibitors for human brain memapsin 2 (β -sevetase)," *J Am Chem Soc* 122(14):3522-3523 (2000).

HONG, et al., "Structure of the protease domain of memapsin 2 (β -secretase) complexed with inhibitor," *Science* 290:150-153 (2000).

LIN, et al., "Human aspartic protease memapsin 2 cleaves the β -secretase site of β -amyloid precursor protein," *PNAS* 97(4):1456-1460 (2000).

TURNER, et al., "Substrate specify of memapsin 2 (β -secretase): basis for inhibitor drug design for Alzheimer's disease," Experimental Biology 2001 c/o *FASEB* Office of Scientific Meetings March 31-April 4, 2001, Orlando, Florida. (Abstract)

U.S.S.N.: 09/603,713
Filed: June 27, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: March 7, 2001


ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

U.S.S.N.: 09/603,713
Filed: June 27, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT


Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: March 7, 2001



Kimberly L. Adams

Substitute for form 1449A/PTO <div style="display: flex; align-items: center;">  <div style="margin-left: 20px;"> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p>(use as many sheets as necessary)</p> </div> </div>		<div style="text-align: center;">Complete if Known</div> <table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">09/603,713</td> </tr> <tr> <td>Filing Date</td> <td>June 27, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Jordan J.N. Tang</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>OMRF 182</td> </tr> </table>		Application Number	09/603,713	Filing Date	June 27, 2000	First Named Inventor	Jordan J.N. Tang	Group Art Unit		Examiner Name		Attorney Docket Number	OMRF 182
Application Number	09/603,713														
Filing Date	June 27, 2000														
First Named Inventor	Jordan J.N. Tang														
Group Art Unit															
Examiner Name															
Attorney Docket Number	OMRF 182														
Sheet 1	of 2														


[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	99/64587	A1	Rhon-Poulenc Rorer	12-16-1999		
		WO	00/17369	A3	Pharmacia & Upjohn Co.	03-30-2000		
		WO	00/23576	A3	Vivian Hook	04-27-2000		
		WO	00/47618	A2	Elan Pharmaceuticals, Inc.	08-17-2000		
		WO	00/58479	A1	Amgen, Inc.	10-05-2000		
		WO	00/77030	A1	Elan Pharmaceuticals, Inc	12-21-2000		

Examine Signature		Date Considered	
----------------------	--	--------------------	--

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.**




Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/603,713
				Filing Date	June 27, 2000
				First Named Inventor	Jordan J.N. Tang
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	OMRF 182



OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ERMOLIEFF, et al., "Proteolytic activation of recombinant Pro-memapsin 2 (Pro- -secretase) studied with new flourogenic substrtes," <i>Biochemistry</i> 39(40):12450-12456 (2000).	
		GHOSH, et al., "Design of potent inhibitors for human brain memapsin 2 (-sevietase)," <i>J Am Chem Soc</i> 122(14):3522-3523 (2000).	
		HONG, et al., "Structure of the protease domain of memapsin 2 (-secretase) complexed with inhibitor," <i>Science</i> 290:150-153 (2000).	
		LIN, et al., "Human aspartic protease memapsin 2 cleaves the -secretase site of -amyloid precursor protein," <i>PNAS</i> 97(4):1456-1460 (2000).	
		TURNER, et al., "Substrate specify of memapsin 2 (-secretase): basis for inhibitor drug design for Alzheimer's disease," <i>Experimental Biology 2001 c/o FASEB Office of Scientific Meetings March 31-April 4, 2001, Orlando, Florida. (Abstract)</i>	

Examiner's Signature	Date Considered
-------------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+